Skip to main content

Table 2 Clinical & demographic details of MS & control cases

From: Calreticulin and other components of endoplasmic reticulum stress in rat and human inflammatory demyelination

  

MS cases

Control cases

Lab I.D.

Sex/Age (y)

Disease

MS type

   

Lab ID

Sex/Age (y)

Duration (y)

Last relapse

Steroids (Y/N)

Treatment

MS 11/11

M/33

3

RR

5 mo

N

Natalizumab

C2/11

F/45

MS 16/11

F/33

1

RR

1 yr

N

Copaxone

C4/11

F/28

MS 19/11

F/36

3

RR

3 yr

N

Copaxone

C7/11

M/22

MS 24/11

F/32

12

RR

2 yr

N

Naltrexone

C13/11

M/49

MS 31/11

M/49

3

RR

1 yr

N

Natalizumab

C14/11

F/30

MS 32/11

F/44

22

RR

2.5 yr

N

Natalizumab

C16/11

F/33

MS 33/11

F/39

12

RR

1 yr

N

Natalizumab

C17/11

M/31

MS 35/11

F/24

6

RR

2 yr

N

Natalizumab

C23/11

F/82

MS 36/11

F/33

10

RR

2 yr

N

Natalizumab

C24/11

F/39

MS 38/11

F/46

13

RR

3.5 yr

N

Natalizumab

C2/12

F/24

MS 39/11

M/33

6

RR

3.5 yr

N

Natalizumab

C5/12

F/42

MS 41/11

M/29

3

RR

2 yr

N

Natalizumab

  

MS 44/11

F/58

22

RR/SP

NK

N

Copaxone

  

MS 47/11

F/48

5

RR

5 yr

N

Rebif

  
  1. Key: mo months, yr years, NK not known.
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us